[Prostate specific antigen (PSA): impact of a seric marker on the diagnosis and therapeutic management of cancers of the prostate].
Chauvet
B
B
Clinique Sainte-Catherine, Avignon, France.
Jacob
T
T
Davin
J L
JL
Berger
C
C
Vincent
P
P
Reboul
F
F
D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen
Prostate specific antigen (PSA): impact d'un marqueur sérique sur la prise en charge diagnostique et thérapeutique des cancers de prostate.